Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia? Erin SchwengerJane DumontetMary H. H. Ensom Review Article 13 September 2012 Pages: 415 - 428
Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders Venkatesh Pilla ReddyMagdalena KozielskaJohannes H. Proost Review Article 13 September 2012 Pages: 429 - 450
Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients François GlowackiArnaud LionetChristelle Cauffiez Short Communication 13 September 2012 Pages: 451 - 459
Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures Marcel P. H. van den BroekAlwin D. R. HuitemaCatharine M. A. Rademaker Review ArticleOriginal Research Article 13 September 2012 Pages: 461 - 469
Asenapine Pharmacokinetics in Hepatic and Renal Impairment Pierre PeetersHoward BockbraderRik de Greef Original Research Article 13 September 2012 Pages: 471 - 481